This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
The primary objective was to assess the efficacy of PCV13 in the prevention of a first episode of confirmed VT-CAP, defined as the presence of ≥2 prespecified clinical criteria, findings on chest radiography consistent with CAP and a positive vaccine-type–specific urinary antigen test or isolation of vaccine-type S. pneumoniae from blood or another sterile site. The secondary objectives were to assess the efficacy of PCV13 in the prevention of a first episode of confirmed VT-NB/NI CAP, that is., an episode of VT-CAP for which the result of a blood culture and results of cultures of any other sterile site were negative for S. pneumoniae and VT IPD, that is, an episode in which the presence of S. pneumoniae is detected in a sterile site. The different terminologies used in the study have been defined. The safety objective was an evaluation of the safety profile of PCV13 as measured by the incidence rates of serious adverse events for 28 days after vaccination among all participants and for 6 months after vaccination among participants in the safety subgroup.1
Definition of Terminologies1
CAP, community-acquired pneumonia; CAPiTA, Community-Acquired Pneumonia Immunization Trial in Adult; IPD, invasive pneumococcal disease; NB/NI, non-bacteraemic/non-invasive; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; SSUAD, serotype-specific urinary antigen detection assay; VT, vaccine type.
Reference:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
FAQs related to different fields
Learn more
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.